Role of hepatocyte pemt in metabolic dysfunction-associated steatohepatitis (mash)
Active Project Grant Awarded Last action
- Award ID
- F31DK146620
- Recipient
-
University Of Illinois UEI W8XEAJDKMXH3
- Awarding agency
-
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $53,114
Award facts
- Assistance listing
- 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research
- Completion date 0% complete
- Place of performance
- Chicago, IL 60612, USA
Award details come from USAspending.gov.
Description
- Abstract
- Metabolic dysfunction-associated steatotic liver disease (masld) is the leading cause of chronic liver disease. Masld can progress to metabolic dysfunction-associated steatohepatitis (mash) increasing the risk of cirrhosis, liver cancer, and death. Masld is characterized by liver steatosis and at least one cardiometabolic risk factor. Mash is characterized by inflammation, fibrosis, and hepatocellular ballooning. Currently, masld/mash treatments are limited to lifestyle modifications, such as diet and exercise, with only two FDA-approved therapies for advanced mash with fibrosis. Therefore, identifying molecular mechanisms driving masld progression is crucial for developing targeted therapies. Hepatic steatosis results from dysregulated fatty acid (FA) synthesis, storage, and utilization. FAS are also incorporated into phospholipids, primarily phosphatidylcholine (PC) and phosphatidylethanolamine (PE), which are essential for maintaining cellular function. PC and PE are synthesized in the kennedy pathway. In hepatocytes, PE can also be methylated by phosphatidylethanolamine methyltransferase (pemt) to generate PC. Of note, increased steatosis and altered PC and PE levels are associated with masld progression. Interestingly, single-nucleotide polymorphisms of the human pemt gene, which lead to reduced pemt activity, are associated with masld. Moreover, hepatic pemt expression is reduced in patients with mash. In mice, the knockout of pemt exacerbates steatosis and accelerates mash. However, the precise mechanisms by which the loss or reduced activity of hepatocyte pemt contribute to masld progression remain unclear. In this project, we sought to elucidate the role of hepatocyte pemt in maintaining liver health and mitochondrial function, and how the loss of hepatocyte-specific pemt expression in mice may lead to the development of mash. To achieve this goal, in aim 1, we will characterize how hepatocyte- specific pemt knockout alters lipid metabolism and promotes diet-induced mash. We will feed mice a high-FAT and cholesterol diet supplemented with fructose in the drinking water for 4 weeks. We will assess metabolic parameters, hepatic pathology, and liver lipidomic profiles with liquid chromatography coupled with mass spectrometry to evaluate lipid homeostasis. In aim 2 of this project, we will investigate the role of hepatocyte pemt in maintaining mitochondrial function to prevent the progression of masld. Mouse primary hepatocytes will be isolated from mice with different expressions of hepatocyte pemt and treated with pemt activators and/or inhibitors, cultured under in vitro mash conditions. Then, we will assess mitochondrial respiration, function, and dynamics using seahorse and fluorescence-based microscopy. Overall, these studies will provide mechanistic insights into hepatocyte pemt's role in maintaining liver health and mitochondrial function, and how reduced hepatocyte pemt contributes to the progression of masld.
Quick answers
Who received award F31DK146620?
F31DK146620 was awarded to University Of Illinois by National Institute of Diabetes and Digestive and Kidney Diseases (National Institutes of Health) on May 1, 2027.
How much is award F31DK146620 worth?
$53,114 has been obligated on F31DK146620.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award